Efficacy of intra-hepatic arterial chemotherapy (IHAC) vs. sorafenib on advanced hepatocellular carcinoma; a prospective cohort study (ISHCC-cohort)
Phase 3
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000002416
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 700
Inclusion Criteria
Not provided
Exclusion Criteria
1) histrogically confirmed combined type hepatocellular carcinoma or sarcomatous change 2) previous therapy for hepatocellular carcinoma within 30 days 3) inadequate for administration of sorafenib, 5-FU, cisplatin or interferon 4) active double cancer 5) severe complication 6) refractory ascites of pleural effusion 7) inappropriate for entry onto this study in the judgment of the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival
- Secondary Outcome Measures
Name Time Method Progression free survival Response rate Tumor control rate Adverse events